Zydus receives final USFDA nod for skin conditions cream

Zydus Cadila has received the final USFDA approval for marketing of Fluocinonide Cream USP, (US RLD-Vanos Cream) 0.1 per cent. This cream is commonly used for the treatment of various skin conditions such as psoriasis, eczema, dermatis, allergies, rash, etc.

Cadila also stated that the drug will be manufactured at the group’s topical manufacturing facility located in Ahmedabad (Gujarat). As of now, the group has 279 approvals and has so far filed over 386 ANDAs, soon after commencing the filing process in FY2003-04.

Zydus Cadila is considered as an innovative, global pharmaceutical company that is engaged in the discovery, development, manufacturing and marketing of broad range of healthcare therapies. Worldwide, the group has an employee count of around 25,000 who are dedicated in creating healthier communities globally. The company aspires to be a research-based pharmaceutical company by the end of 2020.

On Tuesday, the stock of Cadila Healthcare Ltd closed at Rs 274, down by 1.72 per cent or Rs 4.80 per share. The 52-week high is Rs 352.30 and 52-week low is Rs 206.45 on BSE.